SVB Leerink Continues to Strengthen Healthcare Equity Research Practice with Hire of David Risinger

Rhea-AI Summary

SVB Leerink, an investment bank focused on the innovation economy, has announced the hiring of David Risinger as a Senior Managing Director in its healthcare equity research team. Risinger, previously with Morgan Stanley, brings extensive experience in biopharmaceutical research. His appointment is expected to enhance SVB Leerink's capabilities in providing differentiated research to clients. Director of Research Jim Kelly emphasized Risinger's expertise as a significant asset for the firm's future growth in the healthcare sector.

Positive

• David Risinger's hiring strengthens SVB Leerink's healthcare equity research team.
• Risinger's extensive experience in biopharmaceuticals can elevate research offerings.

Negative

• None.

BOSTON, Jan. 4, 2022 /PRNewswire/ -- SVB Leerink, a leading investment bank serving the innovation economy, announced today that David Risinger, CFA, has joined the firm's healthcare equity research team covering biopharmaceutical companies.

David joins SVB Leerink as a Senior Managing Director reporting to Director of Research, Jim Kelly. David's most recent Wall Street role was the Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to that, David held roles at Merrill Lynch & Co. and Dillon, Read & Co.

"David is a strong addition to SVB Leerink, building upon our leadership across the healthcare industry," said Jim Kelly. "His wealth of expertise covering the biopharma industry and his depth of relationships will serve to elevate our offerings for our clients and partners."

Risinger stated: "I am excited to join SVB Leerink to continue to develop its offering in biopharma research. This is a tremendous opportunity to work with a talented team that has proven its leadership in healthcare equity research and its commitment to producing a deep and differentiated research product for its clients."

To learn more, visit: https://www.svbleerink.com/ 

About SVB Leerink
As a leading investment bank serving the innovation economy, SVB Leerink helps its clients move healthcare and technology forward. With differentiated sector knowledge, deep expertise, and an extensive suite of capital market and advisory solutions, the firm is the innovation economy's partner of choice. SVB Leerink is a wholly-owned subsidiary of SVB Financial Group and is a member of FINRA/SIPC. Learn more at svbleerink.com. [SIVB-L]

SVB Leerink
Contact: Diane Vieira
(617) 918-4097

Weber Shandwick
Contact: Patrick Lovett
(212) 546 7828

View original content to download multimedia:https://www.prnewswire.com/news-releases/svb-leerink-continues-to-strengthen-healthcare-equity-research-practice-with-hire-of-david-risinger-301453852.html

SOURCE SVB Leerink

FAQ

What recent announcement did SVB Leerink make regarding healthcare research?

SVB Leerink announced the hiring of David Risinger as a Senior Managing Director in its healthcare equity research team.

Who is David Risinger and what is his previous experience?

David Risinger has joined SVB Leerink from Morgan Stanley, where he led US Major and Specialty Pharmaceuticals Equity Research.

How will David Risinger's role impact SVB Leerink?

His expertise in biopharmaceuticals is expected to enhance SVB Leerink's research capabilities and client offerings.

When did this announcement occur?

The announcement was made on January 4, 2022.

What is the significance of this hiring for SVB Leerink?

It bolsters the firm's leadership in healthcare equity research and aims to improve client service.